Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M406565200 on October 15, 2004

J. Biol. Chem., Vol. 279, Issue 53, 55609-55617, December 31, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/53/55609    most recent
M406565200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, J.
Right arrow Articles by Ma, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, J.
Right arrow Articles by Ma, X.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Synergistic Activation of Interleukin-12 p35 Gene Transcription by Interferon Regulatory Factor-1 and Interferon Consensus Sequence-binding Protein*

Jianguo Liu{ddagger}, Xiuqin Guan{ddagger}, Tomohiko Tamura§, Keiko Ozato§, and Xiaojing Ma{ddagger}

From the {ddagger}Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021 and §Laboratory of Molecular Growth Regulation, NICHD, National Institutes of Health, Bethesda, Maryland 20892

Received for publication, June 11, 2004 , and in revised form, October 12, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Interferon regulatory factor-1 (IRF-1) and interferon consensus sequence-binding protein (ICSBP or IRF-8) are two members of the IRF family of transcription factors that play critical roles in interferon signaling in a wide range of host responses to infection and malignancy. Interleukin-12 (IL-12) is a key factor in the induction of innate resistance and generation of T helper type 1 cells and cytotoxic T lymphocytes. In this work, we find that ICSBP-deficient macrophages are highly defective in the production of IL-12. The defect is also observed at the level of IL-12 p40 and p35 mRNA expression. Transcriptional analyses revealed that ICSBP is a potent activator of the IL-12 p35 gene. It acts through a site localized to –226 to –219, named ICSBP-response element (ICSBP-RE), in the human IL-12 p35 promoter through physical association with IRF-1 both in vitro and in vivo. Co-expression of ICSBP and IRF-1 synergistically stimulates the IL-12 p35 promoter activity. Mutations at the ICSBP-RE results in the loss of protein binding as well as transcriptional activation by ICSBP alone or together with IRF-1. This study provides novel mechanistic information on how signals initiated during innate and adaptive immune responses synergize to yield greater IL-12 production and sustained cellular immunity.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Interferon regulatory factors (IRFs)1 constitute a family of nine mammalian transcription factors (IRF-1–9) that commonly possess a novel helix-turn-helix DNA binding motif. Members of IRF family are typically induced following microbial infections. The first discovered member of this family, IRF-1, has a remarkable functional diversity in the regulation of cellular response in host defense. IRF-1 selectively targets different sets of genes in various cell types in response to diverse cellular stimuli and evokes appropriate innate and adaptive immune responses (1). It has been firmly established as a critical effector molecule in IFN-{gamma}-mediated signaling and in the development and function of NK, NK T cells, and cytotoxic T lymphocytes (2–7). IRF-1 also has direct anti-proliferative effects, thus acting as a tumor suppressor and tumor susceptibility gene. Interferon consensus sequence-binding protein (ICSBP)/IRF-8 is restricted in its expression to myeloid and lymphoid cell lineages. It can function both as a transcriptional repressor and an activator depending on the partners with which it interacts, and it plays crucial roles in myeloid differentiation, generation of plasmacytoid dendritic cells (8), macrophage activation, and tumor suppression (1, 9).

IL-12 is a heterodimeric cytokine produced primarily by macrophages and dendritic cells in both innate and adaptive immune responses. It is a key factor in the induction of T cell-dependent and independent activation of macrophages, NK cells, generation of T helper type 1 cells and CTL, induction of opsonic complement-fixing antibodies, and resistance to intracellular infections (10). The genes encoding the two heterologous chains of IL-12, p40 and p35, are located on different human and mouse chromosomes. Together, p40 and p35 form the biologically active IL-12 (also called p70). The highly coordinated expression of p40 and p35 genes to form IL-12 p70 in the same cell type at the same time is essential for the initiation of an effective immune response. The production of IL-12 p40 in activated professional antigen-presenting cells is generally in great excess over that of the p35 chain, making the latter molecule a limiting step in the formation of bioactive IL-12 (11).

Previous studies by us and others have revealed an intimate relationship between IRF-1, ICSBP, and IL-12 in that IRF-1 acts as a critical component of IFN-{gamma} signaling in the selective activation of the IL-12 p35 transcription (12) in synergy with LPS-mediated events (13, 14) and that IRF-1 and ICSBP cooperatively regulate the transcription of IL-12 p40 gene in IFN-{gamma}-amplified IL-12 production (15, 16). In this work, we show that ICSBP and IRF-1, activated primarily by IFN-{gamma}, also cooperate in their transcriptional activation of the IL-12 p35 gene by directly binding to a specific site in the human IL-12 p35 promoter. This study provides additional mechanistic information regarding how innate and adaptive immune activation jointly lead to greater IL-12 production and persistent inflammatory responses.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Mice—ICSBP–/– mice breeding pair were originally obtained from Dr. Keiko Ozato (National Institutes of Health). All of the mice used in the experiment were female and 6–8 weeks old. Mice were housed in cages with filter tops in a laminar flow hood and fed food and acid water ad libitum.

Cells—The murine macrophage cell line RAW 264.7 (RAW cells hereafter) was obtained from American Type Culture Collection and maintained in RPMI 1640 medium supplemented with 2 mM glutamine, 100 units/ml penicillin and streptomycin, and 10% FBS (endotoxin <1 ng/ml; Hyclone). Mouse inflammatory peritoneal exudate macrophages were obtained by lavage 4 days after injection of sterile 3% thioglycolate broth (1 ml of intraperitoneal). Cells were washed and resuspended in RPMI 1640 medium containing 10% fetal calf serum and standard supplements. Macrophages were plated in 24-well tissue culture dishes (0.5 x 106 cells/well). After 2 h of incubation to allow for adherence of macrophages, monolayers were washed three times to remove nonadherent cells and incubated with RPMI 1640 medium containing 10% fetal calf serum and standard supplements. The next day, some of the wells were treated with 1 µg/ml LPS and 10 ng/ml IFN-{gamma} in a final volume of 1 ml or 10 ng/ml IFN{gamma} first for 16 h (priming) followed by LPS.

Human blood derived-monocytes were isolated from fresh blood by Ficoll/Hypaque gradient centrifugation. Mononuclear cells were incubated for 1 h in polystyrene tissue culture flasks (Falcon, BD Biosciences). After 1 h of incubation to allow for adherence of monocytes, monolayers were washed three times to remove nonadherent cells and incubated with RPMI 1640 medium containing 10% fetal calf serum and standard supplements. The treatment of human monocytes is the same as above unless otherwise stated.

Reagents—All of the antibodies used in this study were purchased from Santa Cruz Biotechnology, Inc. Expression vector ICSBP and control LK440 were provided by Keiko Ozato. All of the plasmid DNA were prepared with Qiagen Endo-free Maxi-Prep kits. Recombinant human and murine IFN-{gamma} was purchased from Genzyme (Boston, MA). LPS from Escherichia coli 0217:B8 and thioglycolate medium were purchased from Sigma.

ELISA—Supernatants from macrophage cultures were harvested at 6, 12, and 24 h after LPS stimulation and stored at –70 °C. Mouse IL-12 p40 and p70 were detected by using the OPT-EIA ELISA kit (BD Biosciences) according to the manufacturer's instructions. Concentrations were calculated by regression analysis of a standard curve.

RNase Protection Assay (RPA)—Mouse peritoneal macrophages were pretreated with IFN-{gamma} for 16 h followed by treatment with LPS for an additional 4 h. 10 µg of total RNA for each determination was subjected to a multiprobe RNase protection kit (BD Biosciences), mCK2b, for mouse according to the manufacturer's instructions.

Quantitative real-time PCR (qRT-PCR)—To determine the level of IL-12 p35 mRNA by quantitative real time PCR, we used a modified protocol from Rajeevan et al. (17). cDNA converted from 1 µg of total RNA was diluted in a several concentrations. Diluted cDNA was mixed with a pair of primers (10 µM) derived from mouse IL-12 p35 or glyceraldehyde-3-phosphate dehydrogenase cDNA sequences and SYBR green PCR master mixture (Applied Biosystem) in a 15-µl volume. PCR cycling was performed as follows: 2 min at 50 °C; 10 min at 95 °C for 1 cycle followed by 40 cycles at 15 s at 95 °C; and 1 min at 60 °C. The PCR primers used were: forward primer, 5'-AAATGAAGCTCTGCATCCTGC-3', and reverse primer, 5'-TCACCCTGTTGATGGTCACG-3', for mouse IL-12 p35; forward primer, 5'-AACT TTGGCATTGTGGAAGG-3', and reverse primer, 5'-ACACATTGGGGGTAGGAACA-3', for mouse glyceraldehyde-3-phosphate dehydrogenase.

Nuclear Extract Preparation—Nuclear extracts for Western blot and DNA affinity binding assay were prepared according to the methods of Schreiber et al. (18).

Western Blotting—SDS-PAGE was performed according to Laemmli (19). Gels were electroblotted to polyvinylidene difluoride membranes and blocked in 5% milk in Tris buffer, pH 8.0. Primary antibody was added at the concentration of 1 µg/ml in Tris buffer containing 1% milk powder and left overnight at 4 °C. After extensive washing, secondary antibody conjugated to horseradish peroxidase was added at a 1:5000 dilution in 5% milk. After extensive washing, blots were subjected to enhanced chemiluminescence detection (PerkinElmer Life Sciences).

Transfection Assay—Transient transfections were performed by electroporation as described previously (20).

DNA Affinity Binding Assay—Complementary biotinylated oligonucleotides encompassing the human IL-12 p35 promoter ICSBP-RE (–235/–208) or the mutant ICSBP-RE were synthesized and annealed. 4 µg of biotinylated double-stranded DNA were conjugated to 200 µl of streptavidin-bound magnetic beads (Dynabeads, M280; Dynal) in binding/washing buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.1 M NaCl) for 30 min at room temperature. Unconjugated DNA was collected with a magnetic particle concentrator. DNA-conjugated beads were then blocked by 0.5% bovine serum albumin in TGEDN buffer (120 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.1 M NaCl, 1 mM dithiothreitol, 0.1% Triton X-100, 10% glycerol) at room temperature for 1 h. Beads were washed once in TGEDN buffer and resuspended in 100 µl of TGEDN. 20-µl beads conjugated to 4 µg of DNA were equilibrated with TGEDN buffer and incubated with 1000 µg of RAW cell nuclear extracts and 20 µg of herring sperm DNA (Sigma) at 4 °C for 2 h. Beads were washed in TGEDN buffer, and bound materials were eluted in 20 µl of the same buffer supplemented with 0.5% SDS and 1 M NaCl. Eluted materials and unconjugated protein were separated by 12% SDS-PAGE and detected by immunoblot analysis using rabbit anti-IRF-1 antibody with the enhanced chemiluminescence kit. Nuclear extracts were prepared from RAW cells treated with 10 ng/ml IFN-{gamma} for 16 h followed by incubation with LPS alone or plus IFN-{gamma} for an additional 4 h.

Co-immunoprecipitation—RAW 264.7 cells were activated with 10 ng/ml IFN-{gamma} for 5 h. The cells then were washed with cold phosphate-buffered saline, and nuclear extract was harvested. The nuclear extract was precleared by adding 20 µl of protein G-agarose and incubating at 4 °C for 1 h on a rocker. Precleared nuclear extract (500 µg) was incubated with 2 µg of IRF-1 or ICSBP antibody (Santa Cruz Biotechnology, Inc.) in the presence of 20 µl of 50% (v/v) protein G-agarose overnight at 4 °C with gentle rocking. After three washings with phosphate-buffered saline, precipitated complexes were solubilized by boiling in SDS buffer, fractionated by 12% SDS-PAGE, and transferred to polyvinylidene difluoride membrane. Western blotting was performed using an ICSBP or IRF-1 antibody.

Chromatin Immunoprecipitation (ChIP) Assay—The ChIP procedure was performed using an assay kit according to the manufacturer's instructions (Upstate Biotechnology). 107 human peripheral blood monocytes were stimulated with 10 ng/ml IFN-{gamma} priming and 1 µg/ml LPS or alone and cross-linked by 1% formaldehyde for 10 min at 37 °C. Nuclei were prepared and subjected to sonication to obtain DNA fragments ranging from 200 to 1000 bp. Chromatin fractions were precleared with protein G-agarose beads followed by immunoprecipitation overnight at 4 °C with 2 µg of anti-IRF-1 antibody or anti-ICSBP antibody and its control antibody. Cross-linking was reversed for4hat 65 °C and was followed by proteinase K digestion. DNA was purified and subjected to PCR. The input DNA was diluted 200 times before PCR. The input and precipitated DNA were PCR-amplified by primers encompassing the ICSBP site in the human IL-12 p35 promoter (5' primer, 5'-GCGAACATTTCGCTTTCATT-3', and 3' primer, 5'-ACTTTCCCGGGACTCTGGT-3') in a buffer containing 2 mM MgCl2. The samples were amplified for 34 cycles by PCR and analyzed by electrophoresis on a 1.2% agarose gel or analyzed by quantitative real-time PCR as described above.

Statistical Analysis—Student's t test was performed wherever applicable. Mean ± S.D. is shown unless otherwise indicated.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
IL-12 p40 and p70 Production Is Defective in ICSBP–/– mice—To determine the role of ICSBP in the regulation of IL-12 production, we obtained inflammatory peritoneal macrophages from ICSBP–/– mice (on C57BL/6 background) and control wild type animals and stimulated them in vitro with LPS or primed with IFN-{gamma} followed by LPS stimulation. IL-12 p40 and p70 production at various times over a period of 24 h was measured by specific ELISA. Because of the lack of a p35-speicifc ELISA due to the fact that it is secreted only as a heterodimer, the measurement of p70 production is a generally accepted indicator of IL-12 p35 production due to the one to one ratio of the p40-p35 interaction. As shown in Fig. 1, IL-12 p40 production stimulated by LPS alone (A) or IFN-{gamma} plus LPS (B) was strongly impaired in ICSBP–/– macrophages compared with wild type or ICSBP+/– cells. Similarly, IL-12 p70 production induced by LPS (C) or IFN-{gamma} plus LPS (D) was virtually absent in ICSBP–/– cells. These results indicate that ICSBP is an essential regulator of IL-12 p40 and p70 production.



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 1.
Impact of ICSBP deficiency on IL-12 p40 and p70 production. IL-12 p40 (A and B) and p70 (C and D) were measured by ELISA from cell-free supernatants of thioglycolate-elicited inflammatory mouse peritoneal macrophage cultures (0.5 x 106 cells in 1 ml) stimulated with LPS (A and C) or primed with IFN-{gamma} for 16 h followed by LPS (B and D) for indicated times in hours. Filled square, wild type macrophages (WT); asterisk, ICSBP+/– cells; open circle, ICSBP–/– macrophages. Results shown are the mean ± S.D. of four independent experiments.

 
IL-12 p40 and p35 mRNA Expression Is Impaired in ICSBP–/– Macrophages—To determine the effects of ICSBP deficiency on IL-12 p40 and p35 gene expression, we examined their steady-state mRNA expression by RPA and by qRT-PCR. The RPA (Fig. 2A) shows that the level of IL-12 p40 mRNA induced by LPS alone or IFN-{gamma} plus LPS was comparable between wild type and ICSBP+/– peritoneal macrophages (lane 3 versus lane 7 and lane 4 versus lane 8), whereas its level was significantly reduced in ICSBP–/– cells activated by IFN-{gamma} and LPS (lanes 4 and 8 versus lane 12), a result consistent with our previous finding (16). IL-12 p35 mRNA levels were reduced in ICSBP–/– cells activated with LPS alone (lane 11) or IFN-{gamma} plus LPS (lane 12). The qRT-PCR analysis (Fig. 2B) shows more definitively that both LPS- and IFN-{gamma}/LPS-induced IL-12 p35 mRNA levels were drastically reduced in ICSBP–/– macrophages. These data strongly indicate that ICSBP regulates both IL-12 p40 and p35 mRNA expression.



View larger version (67K):
[in this window]
[in a new window]
  		FIG. 2.
Impact of ICSBP deficiency on IL-12 p40 and p35 mRNA expression. Total RNA were isolated from peritoneal macrophages of wild type (WT) (+/+), ICSBP heterozygous (+/–), and ICSBP homozygous (–/–) mice and subjected to analysis by RPA (A) or by qRT-PCR (B). 10 µg of RNA were used in the RPA for the expression of the indicated cytokines using MCK2b (BD Biosciences). The RPA data are representative of two separate experiments with very similar results. The qRT-PCR data are the mean ± S.D. from three experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. MIF, macrophage migration inhibitory factor.

 
ICSBP Activates the IL-12 p35 Gene Transcription through a Proximal Promoter Region—We had previously established the molecular mechanism whereby ICSBP regulates IL-12 p40 gene transcription (16). In this work, we sought to elucidate how ICSBP regulates IL-12 p35 gene transcription by first examining the response of the human IL-12 p35 promoter to the effects of ICSBP in a well established transient transfection system in RAW cells (12). Fig. 3A shows that ICSBP expression stimulated the IL-12 p35 promoter-driven luciferase activity in a dose-dependent manner in RAW cells under all conditions, but by far the greatest stimulation was seen in IFN-{gamma}/LPS-activated cells (filled diamonds). Note that, although difficult to discern in this graph because of the relatively low scale, the IL-12 p35 promoter was highly inducible by IFN-{gamma} and LPS (10–20-fold) without exogenous ICSBP, as is the case here and as we have shown previously (12). An analysis of endogenous ICSBP protein expression revealed that ICSBP was primarily induced by IFN-{gamma} in the nucleus, not in the cytoplasm, and that LPS treatment alone had little effect (Fig. 3B). These data clearly demonstrate the ability of ICSBP, primarily as an IFN-{gamma}-inducible transcription factor, to activate IL-12 p35 gene transcription.



View larger version (28K):
[in this window]
[in a new window]
  		FIG. 3.
ICSBP activates IL-12 p35 promoter through a specific region. A, a 1143-bp human IL-12 p35 promoter-luciferase reporter construct (12) was transiently transfected into RAW cells by electroporation together with increasing amounts of an ICSBP expression vector or its control vector LK440 (16). Cells were stimulated with LPS alone (7 h) or IFN-{gamma} (16 h) followed by LPS. Luciferase activity from each construct was measured from cell lysates. Results shown are the mean ± S.E. of three independent experiments. B, the endogenous ICSBP protein expression in the cytoplasm and in the nucleus of RAW 264.7 cells was analyzed by Western blot using an affinity-purified polyclonal anti-ICSBP antibody under the same cellular stimulations. The membrane was subsequently stripped and reprobed with anti-{beta}-actin (cytoplasm) and anti-PU.1 (nucleus) antibodies, respectively, to ensure equivalent protein loading. C, various truncation constructs of the human IL-12 p35 promoter-luciferase reporter were transiently transfected into RAW cells by electroporation together with an ICSBP expression vector or its control vector LK440. Cells were left alone or treated with LPS (7 h). ICSBP-stimulated luciferase activity from each construct was measured from cell lysates and normalized to the activity obtained with the control vector, respectively. Results shown are the mean ± S.E. of four independent experiments. The promoter coordinates all refer to the monocyte-specific transcription initiation site located at +1 (12).

 
To further explore the molecular mechanism whereby IFN{gamma} regulates IL-12 p35 transcription through ICSBP, we dissected the human IL-12 p35 promoter by sequentially deleting the full-length promoter, a 1143-bp genomic fragment (12), from the 5' end. The transcriptional start site of the human IL-12 p35 gene in macrophages has been mapped previously (21). Because ICSBP is primarily induced by IFN-{gamma}, not LPS treatment, in macrophages (Fig. 3B), we stimulated RAW 264.7 cells with LPS in all of our transfection studies to provide the other essential set of transcription factors for maximally induced IL-12 p35 gene expression (12). As shown in Fig. 3C, the full-length IL-12 p35 promoter (–1082 to +61) was highly responsive to stimulation by ICSBP in resting cells (~8-fold compared with control vector-transfected cells) and in LPS-activated cells (~27-fold). Sequential deletion of the full-length promoter down to –231 had no adverse impact on the inducibility of the p35 promoter by ICSBP. Note that the –231/+61 construct has lost a previously identified element, IRF-E-(–245 to –236), that is critical for response to IRF-1 (12). The loss of the IRF-E apparently had no effect on the response to ICSBP. A further deletion of 17 bp (to –214) resulted in a moderate loss of the ICSBP response in resting cells and a dramatic loss of response in LPS-stimulated cells, indicating the presence of a critical cis-element(s) in this region involved in response to ICSBP. By this approach, we identified the 17-bp region between –231 and –214 as a site containing a ICSBP-RE. Within this region, the GeneToolTM program (Double Twist, now defunct) predicted an IFN-{gamma}-regulated element consensus sequence ({gamma}-IRE_CS), 5'-CTGGAGGC-3', from –225 to –219.

Localization of ICSBP-RE—To assess whether the predicted sequence 5'-CTGGAGGC-3' located at –226 to –219 was critical for ICSBP response, we introduced 2-bp substitutions into this site in the context of the –231/+61 of the IL-12 p35 promoter and measured their response to ICSBP by transfection into RAW 264.7 cells treated with LPS. One of the substitution mutants (Fig. 4A) showed a different response from the wild type control in that the mutation reduced the ability by >70% of the –231/+61 IL-12 p35 promoter to stimulation by the co-transfected ICSBP without LPS (Fig. 4B, compare column 3 with column 1), similarly to the 5'-deletion construct of –214/+61 that has lost the entire 17-bp region including the ICSBP-RE (column 5). Secondary to that, the LPS-induced promoter activity of the mutant was also reduced proportionally (compare column 4 with column 2).



View larger version (29K):
[in this window]
[in a new window]
  		FIG. 4.
Localization of an ICSBP-RE. A, sequence of wild type (Wt) and mutant (Mut) of the putative ICSBP-RE in the IL-12 p35 promoter located at –226 to –219. The 2-bp mutation in the mutant ICSBP-RE is underlined. B, site-specific mutations (2 bp) were introduced into the ICSBP-RE at –226 to –225 in the context of the minimal promoter (–231/+61). The wild type, mutant, and a downstream (–214/+61) construct were transfected into RAW cells, respectively, together with the ICSBP expression vector or its control. Cells were stimulated with LPS (7 h). Luciferase activity was measured from cell lysates and expressed as fold of stimulation over that of the same reporter cotransfected with the empty vector. Student's t test was performed for the comparisons indicated by the inclusive brackets. Results are the mean ± S.E. from 9–11 independent experiments.

 
ICSBP and IRF-1 Physically Interact and Synergize to Activate IL-12 p35 Transcription—Given the data shown in Fig. 4, we were interested in understanding the physical aspect of the ICSBP activity, i.e. DNA-protein interactions at the ICSBP-RE. However, by conventional electrophoretic mobility shift assay, we were unable to detect significant DNA binding activity at this site. We reasoned that this may be because of the low levels or low affinity of nuclear binding proteins that could specifically recognize this DNA element. Thus, we resorted to the DNA affinity binding assay, which allows the detection of low affinity or low levels of nuclear binding activities (12, 16). By this method, we still could not detect the presence of ICSBP. Surprisingly, we saw weak IRF-1 binding to this site in response to IFN-{gamma} and LPS in a sequence-specific manner since the mutant probe failed to recognize the binding (Fig. 5A). This result was corroborated by co-immunoprecipitation, which showed that an anti-IRF-1 IgG was able to pull down ICSBP in IFN-{gamma}-stimulated RAW 264.7 cells (Fig. 5B, top panel) or by reciprocal co-immunoprecipitation with anti-ICSBP (Fig. 5B, bottom), demonstrating their co-presence in the same complex that interacts with the ICSBP-RE (not necessarily directly interacting), as is the case in IL-12 p40 gene transcription (16).



View larger version (40K):
[in this window]
[in a new window]
  		FIG. 5.
ICSBP synergizes with IRF-1 to activate IL-12 p35 transcription through physical interaction. A, DNA affinity assay. The assay was performed using nuclear extracts isolated from RAW 264.7 cells following appropriate stimulation as indicated and the wild type (wt) and mutant (Mut) ICSBP-RE probes covering the –235/–208 region of the human IL-12 p35 promoter. The final step of analysis shown here was a Western blot to visualize the presence of IRF-1 in the complex that bound to the ICSBP-RE. B, co-immunoprecipitation was performed with nuclear extract isolated from resting or IFN-{gamma}-stimulated RAW 264.7 cells with an anti-IRF-1 antibody (top) or anti-ICSBP antibody (bottom) and their isotype-matched control IgG in the immunoprecipitation step. Input refers to nuclear extract subjected to Western blot (WB) analysis for ICSBP or IRF-1 presence without the immunoprecipitation (IP) step. C, the wild type full-length IL-12 p35 promoter-luciferase reporter was co-transfected into RAW 264.7 cells with IRF-1 or ICSBP expression vector or their respective control vector CV1 (LK440) or CV2 (pAct-C). Following LPS stimulation (7 h), luciferase activity was measured from total cell lysate. Results are the mean ± S.E. from three independent experiments. D, the same kind of experiment as described in C was performed with the exception that the wild type (WT) and mutant IL-12 p35 promoter-reporter constructs in the context of –231 to +61 were used. Results are the mean ± S.E. from three independent experiments.

 
The above results led us to reason that IRF-1 may be involved in ICSBP-stimulated IL-12 p35 transcription. We tested this hypothesis by determining whether ICSBP and IRF-1 could stimulate IL-12 p35 transcription synergistically. Fig. 5C shows that the full-length IL-12 p35 promoter (–1083/+61) was synergistically activated by exogenous ICSBP and IRF-1 but only in LPS-stimulated cells, not in resting cells. The –231/+61 construct was also synergistically activated by ICSBP and IRF-1 (Fig. 5D). Moreover, this synergy was dependent on the ICSBP-RE because the ICSBP-RE mutant lost significantly its ability to respond to ICSBP and IRF-1 synergistically (Fig. 5D).

ICSBP and IRF-1 Both Bind to the ICSBP-RE in Vivo in Activated Primary Monocytes—To determine whether ICSBP and IRF-1 could bind to the endogenous IL-12 p35 promoter at the ICSBP-RE in vivo in primary human monocytes, we performed ChIP using a pair of primers flanking the ICSBP-RE for PCR amplification (Fig. 6A). Fig. 6B shows that both IRF-1 and ICSBP binding to the ICSBP-RE were readily detectable in monocytes stimulated with IFN-{gamma} but not with LPS (the faint band seen in lanes 1 and 2 of the anti-ICSBP panel were likely artifacts because of their different size). The combination of IFN-{gamma} and LPS stimulation further enhanced ICSBP binding (lane 4). These data was further confirmed by qRT-PCR (Fig. 5C) in that both IFN-{gamma} and IFN-{gamma} plus LPS strongly induced ICSBP and IRF-1 binding to the ICSBP-RE. The pattern of the endogenous ICSBP nuclear expression was consistent with its binding activity in vivo (Fig. 5D). These results clearly demonstrate that ICSBP and IRF-1 could bind to the endogenous IL-12 p35 ICSBP-RE in primary monocytes in response principally to IFN-{gamma} stimulation.



View larger version (45K):
[in this window]
[in a new window]
  		FIG. 6.
ICSBP and IRF-1 bind to IL-12 p35 promoter in vivo. A, sequence of human IL-12 p35 promoter containing ICSBP-RE. The sequences of the PCR primers used to perform ChIP and ICSBP-RE are indicated. B, ChIP analysis was performed in human blood derived monocytes as described under "Materials and Methods." The amplified human genomic fragment derived from the endogenous IL-12 p35 promoter encompassing the ICSBP-RE is indicated. Gel size markers are labeled in bp. The control antibody was an isotype-matched IgG. Input DNAs were used as controls, which should not vary significantly across all of the samples. C, qRT-PCR was performed with the newly extracted DNA samples, the same as that used in B, to quantify the binding activity of IRF-1 (top) and ICSBP (bottom) to the ICSBP-RE. Data are expressed as relative expression, i.e. fold increase of all of the conditions versus medium alone with anti-IRF-1 or anti-ICSBP antibody (Ab). M, medium; L, LPS; {gamma}, IFN-{gamma}. D, ICSBP expression in the nucleus. Nuclear extracts were isolated from primary human monocytes following stimulation with IFN-{gamma} (20 h) or LPS (4 h) or both and then subjected to Western blot analysis using an anti-ICSBP Ab. Afterward, the membrane was stripped and reprobed with anti-PU.1 Ab to confirm equivalent protein loading.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
IFN{gamma}-mediated enhancement of IL-12 production represents the convergence of signals derived from innate and adaptive immune responses. IFN-{gamma} is produced mainly by NK cells during innate responses and by activated T lymphocytes during adaptive immunity. The exposure of professional antigen-presenting cells to IFN-{gamma} activates IRFs including IRF-1 and ICSBP that are critical for maximal IL-12 synthesis when coupled with microbial stimuli such as LPS. This work builds on our previous studies and further elucidates the mechanism whereby the two signals initiated by innate and adaptive stimuli, respectively, converge to induce high levels of IL-12 production and ensure highly active and persistent NK and T helper type 1 responses.

The critical role of ICSBP in IL-12 production is illustrated in the observation that IL-12 p35 and p40 mRNA expression is impaired in ICSBP-deficient macrophages (Fig. 2) and that IL-12 p40 synthesis is severely reduced (Fig. 1, A and B), whereas IL-12 p70 production is virtually absent (Fig. 1, C and D). There is a quantitative discrepancy between reduced IL-12 p35 and p40 mRNA expression in ICSBP–/– macrophages on the one hand and the total lack of IL-12 p70 synthesis by these cells on the other. This may be explained by the possibility that the reduced levels of IL-12 p40 and p35 proteins in ICSBP–/– cells fall below a certain "threshold" for the formation of IL-12 heterodimers. Alternatively, although less likely, the ICSBP deficiency causes an indirect effect on the assembly or secretion of the IL-12 p70 heterodimer. Post-translational regulation of IL-12 production has been reported previously (22–24). That in our transfection system, LPS coupled with forced ICSBP expression failed to induce significant activation of the IL-12 p35 promoter compared with unstimulated cells (Fig. 3A) is consistent with the fact that IL-12 p35 transcriptional activation also requires IRF-1, which is induced by IFN-{gamma} but not by LPS (12). It should be stressed that the transcriptional activation of IL-12 p35 requires two signals, one typically provided by LPS and the other by IFN-{gamma}. The LPS-initiated signal induces the activation of such transcription factors as NF{kappa}B and Sp-1 that are essential for IL-12 p35 transcription (12–14). The IFN-{gamma}-initiated signal induces IRF-1 and ICSBP that are critical for IL-12 p35 transcription and p70 production (12, 14). Both signals are necessary (either signal alone is not sufficient) to activate IL-12 p35 transcription. The fact that the ICSBP response of the IL-12 p35 ICSBP-RE mutant promoter was reduced by ~70% regardless of the absence or presence of LPS (Fig. 4B) suggests that the LPS response of the promoter is not dependent on the integrity of the ICSBP-RE. In other words, the ICSBP and LPS responses of the IL-12 p35 promoter are separate.

We were unable to detect a direct interaction of ICSBP with the ICSBP-RE in vitro but able to do so in vivo by ChIP (Fig. 6B). This could be due to a low abundance of ICSBP in the complex or due to the shielding of ICSBP from antibody contact by IRF-1 in vitro. This "hindrance" by IRF-1 may not occur in vivo on the chromatin-wrapped IL-12 p35 promoter because, presumably, the conformation in which IRF-1 and ICSBP bind to the ICSBP-RE in the presence of the surrounding chromatin structures does not obstruct access by their respective antibodies during the ChIP procedure (Fig. 6B). Furthermore, other lines of evidence suggest that ICSBP functionally interact with IRF-1. They can synergize to stimulate IL-12 p35 transcription through the ICSBP-RE (Fig. 5C) by binding together to the ICSBP-RE in vivo (Fig. 6B). It should be pointed out that the ICSBP-RE we identified in the human IL-12 p35 promoter does not look like a conventional IRF-E (GAAA(G/C)(T/C)GAAA(G/C)(T/C)) (25) or ISRE ((A/G)NGAAANNGAAACT) (26). Thus, it is possible that ICSBP may interact with this element through an unidentified factor in addition to IRF-1. A third possibility is that ICSBP could enhance IRF-1 binding to the ICSBP-RE through an intermediary but itself does not come into direct contact with DNA.

Based on several studies by us as well as other groups, a model is emerging that schematizes the molecular events that lead to IL-12 production by antigen-presenting cells (Fig. 7 for the IL-12 p35 subunit gene). During the innate phase of an immune response, microbial antigens activate the NF{kappa}B pathway via Toll-like receptors (Toll-like receptor 4 for LPS) in a MyD88-dependent manner (27, 28). Activated NF{kappa}B alone stimulates moderate transcription of IL-12 p35 and p40 genes primarily through p50 and c-Rel (13, 29 –31). The initial small amount of IL-12 is able to stimulate NK cells to produce IFN-{gamma}. IFN-{gamma} can also be produced by activated T cells. IFN-{gamma} then activates IRF-1 and ICSBP, which can bind two sites in the IL-12 p35 promoter, either alone to the IRF-E by IRF-1 (12) or together (ICSBP-RE, Figs. 5 and 6), resulting in much greater levels of transcription of IL-12 p40 (16) and p35 genes (12) and the production of IL-12. The combined activity of IFN-{gamma} and LPS also leads to the activation of Sp1 and its binding to a site in the p35 promoter as part of selective remodeling of a single nucleosome within the –310 to –160 region (14). The combination of signals derived from innate and adaptive immune events stimulate synergistically the production of IL-12 and sustain the inflammatory response and cell-mediated immunity against pathogens.



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 7.
Schematic presentation of the mechanism of transcriptional activation of IL-12 p35 gene. The proximal human IL-12 p35 promoter sequence is shown with several important cis-elements and relative locations indicated. The coordinates indicate the location of the 5' most nucleotide of each element. CM, cytoplasmic membrane; NM, nuclear membrane. See "Discussion" for more details.

 

   FOOTNOTES
 
* This work was supported by National Institutes of Health Grants AI-045899 and CA-79772 (to X. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: Dept. of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Ave., New York, NY 10021. Tel.: 212-746-4404; Fax: 212-746-4427; E-mail: xim2002{at}med.cornell.edu.

1 The abbreviations used are: IRF-1, interferon regulatory factor-1; ICSBP, interferon consensus sequence-binding protein; IL-12, interleukin-12; ICSBP-RE, ICSBP-response element; IFN-{gamma}, interferon-{gamma}; LPS, lipopolysaccharide; ELISA, enzyme-linked immunosorbent assay; RPA, RNase protection assay; qRT-PCR, quantitative real-time PCR; ChIP, chromatin immunoprecipitation; NK, natural kill; IRF-E, IRF-1 response element. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Taniguchi, T., Ogasawara, K., Takaoka, A., and Tanaka, N. (2001) Annu. Rev. Immunol. 19, 623–655[CrossRef][Medline] [Order article via Infotrieve]
  2. Matsuyama, T., Kimura, T., Kitagawa, M., Pfeffer, K., Kawakami, T., Watanabe, N., Kundig, T. M., Amakawa, R., Kishihara, K., Wakeham, A., et al. (1993) Cell 75, 83–97[CrossRef][Medline] [Order article via Infotrieve]
  3. Duncan, G. S., Mittrucker, H. W., Kagi, D., Matsuyama, T., and Mak, T. W. (1996) J. Exp. Med. 184, 2043–2048[Abstract/Free Full Text]
  4. Taki, S., Sato, T., Ogasawara, K., Fukuda, T., Sato, M., Hida, S., Suzuki, G., Mitsuyama, M., Shin, E. H., Kojima, S., Taniguchi, T., and Asano, Y. (1997) Immunity 6, 673–679[CrossRef][Medline] [Order article via Infotrieve]
  5. Ogasawara, K., Hida, S., Azimi, N., Tagaya, Y., Sato, T., Yokochi-Fukuda, T., Waldmann, T. A., Taniguchi, T., and Taki, S. (1998) Nature 391, 700–703[CrossRef][Medline] [Order article via Infotrieve]
  6. Ohteki, T., Yoshida, H., Matsuyama, T., Duncan, G. S., Mak, T. W., and Ohashi, P. S. (1998) J. Exp. Med. 187, 967–972[Abstract/Free Full Text]
  7. Lohoff, M., Duncan, G. S., Ferrick, D., Mittrucker, H. W., Bischof, S., Prechtl, S., Rollinghoff, M., Schmitt, E., Pahl, A., and Mak, T. W. (2000) J. Exp. Med. 192, 325–336[Abstract/Free Full Text]
  8. Tsujimura, H., Tamura, T., and Ozato, K. (2003) J. Immunol. 170, 1131–1135[Abstract/Free Full Text]
  9. Tamura, T., Kong, H. J., Tunyaplin, C., Tsujimura, H., Calame, K., and Ozato, K. (2003) Blood 102, 4547–4554[Abstract/Free Full Text]
  10. Trinchieri, G. (1995) Annu. Rev. Immunol. 13, 251–276[Medline] [Order article via Infotrieve]
  11. Snijders, A., Hilkens, C. M., van der Pouw Kraan, T. C., Engel, M., Aarden, L. A., and Kapsenberg, M. L. (1996) J. Immunol. 156, 1207–1212[Abstract]
  12. Liu, J., Cao, S., Herman, L. M., and Ma, X. (2003) J. Exp. Med. 198, 1265–1276[Abstract/Free Full Text]
  13. Grumont, R., Hochrein, H., O'Keeffe, M., Gugasyan, R., White, C., Caminschi, I., Cook, W., and Gerondakis, S. (2001) J. Exp. Med. 194, 1021–1032[Abstract/Free Full Text]
  14. Goriely, S., Demonte, D., Nizet, S., De Wit, D., Willems, F., Goldman, M., and Van Lint, C. (2003) Blood 101, 4894–4902[Abstract/Free Full Text]
  15. Masumi, A., Tamaoki, S., Wang, I. M., Ozato, K., and Komuro, K. (2002) FEBS Lett. 531, 348–353[CrossRef][Medline] [Order article via Infotrieve]
  16. Wang, I. M., Contursi, C., Masumi, A., Ma, X., Trinchieri, G., and Ozato, K. (2000) J. Immunol. 165, 271–279[Abstract/Free Full Text]
  17. Rajeevan, M. S., Ranamukhaarachchi, D. G., Vernon, S. D., and Unger, E. R. (2001) Methods 25, 443–451[CrossRef][Medline] [Order article via Infotrieve]
  18. Schreiber, E., Matthias, P., Muller, M. M., and Schaffner, W. (1989) Nucleic Acids Res. 17, 6419[Free Full Text]
  19. Laemmli, U. K. (1970) Nature 227, 680–685[CrossRef][Medline] [Order article via Infotrieve]
  20. Ma, X., Chow, J. M., Gri, G., Carra, G., Gerosa, F., Wolf, S. F., Dzialo, R., and Trinchieri, G. (1996) J. Exp. Med. 183, 147–157[Abstract/Free Full Text]
  21. Hayes, M. P., Murphy, F. J., and Burd, P. R. (1998) Blood 91, 4645–4651[Abstract/Free Full Text]
  22. Babik, J. M., Adams, E., Tone, Y., Fairchild, P. J., Tone, M., and Waldmann, H. (1999) J. Immunol. 162, 4069–4078[Abstract/Free Full Text]
  23. Murphy, F. J., Hayes, M. P., and Burd, P. R. (2000) J. Immunol. 164, 839–847[Abstract/Free Full Text]
  24. Carra, G., Gerosa, F., and Trinchieri, G. (2000) J. Immunol. 164, 4752–4761[Abstract/Free Full Text]
  25. Tanaka, N., Kawakami, T., and Taniguchi, T. (1993) Mol. Cell. Biol. 13, 4531–4538[Abstract/Free Full Text]
  26. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. (1994) Science 264, 1415–1421[Abstract/Free Full Text]
  27. Seki, E., Tsutsui, H., Tsuji, N. M., Hayashi, N., Adachi, K., Nakano, H., Futatsugi-Yumikura, S., Takeuchi, O., Hoshino, K., Akira, S., Fujimoto, J., and Nakanishi, K. (2002) J. Immunol. 169, 3863–3868[Abstract/Free Full Text]
  28. Edwards, A. D., Manickasingham, S. P., Sporri, R., Diebold, S. S., Schulz, O., Sher, A., Kaisho, T., Akira, S., and Reise Sousa, C. (2002) J. Immunol. 169, 3652–3660[Abstract/Free Full Text]
  29. Murphy, T. L., Cleveland, M. G., Kulesza, P., Magram, J., and Murphy, K. M. (1995) Mol. Cell. Biol. 15, 5258–5267[Abstract]
  30. Gri, G., Savio, D., Trinchieri, G., and Ma, X. (1998) J. Biol. Chem. 273, 6431–6438[Abstract/Free Full Text]
  31. Sanjabi, S., Hoffmann, A., Liou, H. C., Baltimore, D., and Smale, S. T. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 12705–12710[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
S. Kempe, P. Heinz, E. Kokai, O. Devergne, N. Marx, and T. Wirth
Epstein-Barr Virus-Induced Gene-3 Is Expressed in Human Atheroma Plaques
Am. J. Pathol., July 1, 2009; 175(1): 440 - 447.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
A. la Sala, J. He, L. Laricchia-Robbio, S. Gorini, A. Iwasaki, M. Braun, G. S. Yap, A. Sher, K. Ozato, and B. Kelsall
Cholera toxin inhibits IL-12 production and CD8{alpha}+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function
J. Exp. Med., June 8, 2009; 206(6): 1227 - 1235.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. M. Makela, M. Strengell, T. E. Pietila, P. Osterlund, and I. Julkunen
Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells
J. Leukoc. Biol., April 1, 2009; 85(4): 664 - 672.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
D. Gaucher, R. Therrien, N. Kettaf, B. R. Angermann, G. Boucher, A. Filali-Mouhim, J. M. Moser, R. S. Mehta, D. R. Drake III, E. Castro, et al.
Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses
J. Exp. Med., December 22, 2008; 205(13): 3119 - 3131.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Vila-del Sol, C. Punzon, and M. Fresno
IFN-{gamma}-Induced TNF-{alpha} Expression Is Regulated by Interferon Regulatory Factors 1 and 8 in Mouse Macrophages
J. Immunol., October 1, 2008; 181(7): 4461 - 4470.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
F. B. Hickey, C. F. Brereton, and K. H. G. Mills
Adenylate cycalse toxin of Bordetella pertussis inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK activation in dendritic cells
J. Leukoc. Biol., July 1, 2008; 84(1): 234 - 243.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Fedele, M. Nasso, F. Spensieri, R. Palazzo, L. Frasca, M. Watanabe, and C. M. Ausiello
Lipopolysaccharides from Bordetella pertussis and Bordetella parapertussis Differently Modulate Human Dendritic Cell Functions Resulting in Divergent Prevalence of Th17-Polarized Responses
J. Immunol., July 1, 2008; 181(1): 208 - 216.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. Jayakumar, M. J. Donovan, V. Tripathi, M. Ramalho-Ortigao, and M. A. McDowell
Leishmania major Infection Activates NF-{kappa}B and Interferon Regulatory Factors 1 and 8 in Human Dendritic Cells
Infect. Immun., May 1, 2008; 76(5): 2138 - 2148.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. K. Polumuri, V. Y. Toshchakov, and S. N. Vogel
Role of Phosphatidylinositol-3 Kinase in Transcriptional Regulation of TLR-Induced IL-12 and IL-10 by Fc{gamma} Receptor Ligation in Murine Macrophages
J. Immunol., July 1, 2007; 179(1): 236 - 246.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
J. Liu, X. Guan, and X. Ma
Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-{gamma}-mediated pathways
J. Exp. Med., January 22, 2007; 204(1): 141 - 152.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. E. Thomas, C. L. Galligan, R. D. Newman, E. N. Fish, and S. N. Vogel
Contribution of Interferon-beta to the Murine Macrophage Response to the Toll-like Receptor 4 Agonist, Lipopolysaccharide
J. Biol. Chem., October 13, 2006; 281(41): 31119 - 31130.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Liu and X. Ma
Interferon Regulatory Factor 8 Regulates RANTES Gene Transcription in Cooperation with Interferon Regulatory Factor-1, NF-{kappa}B, and PU.1
J. Biol. Chem., July 14, 2006; 281(28): 19188 - 19195.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
H. W. Murray, C. W. Tsai, J. Liu, and X. Ma
Responses to Leishmania donovani in Mice Deficient in Interleukin-12 (IL-12), IL-12/IL-23, or IL-18
Infect. Immun., July 1, 2006; 74(7): 4370 - 4374.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
F. Spensieri, G. Fedele, C. Fazio, M. Nasso, P. Stefanelli, P. Mastrantonio, and C. M. Ausiello
Bordetella pertussis Inhibition of Interleukin-12 (IL-12) p70 in Human Monocyte-Derived Dendritic Cells Blocks IL-12 p35 through Adenylate Cyclase Toxin-Dependent Cyclic AMP Induction.
Infect. Immun., May 1, 2006; 74(5): 2831 - 2838.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Orabona, P. Puccetti, C. Vacca, S. Bicciato, A. Luchini, F. Fallarino, R. Bianchi, E. Velardi, K. Perruccio, A. Velardi, et al.
Toward the identification of a tolerogenic signature in IDO-competent dendritic cells
Blood, April 1, 2006; 107(7): 2846 - 2854.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Goriely, C. Molle, M. Nguyen, V. Albarani, N. O. Haddou, R. Lin, D. De Wit, V. Flamand, F. Willems, and M. Goldman
Interferon regulatory factor 3 is involved in Toll-like receptor 4 (TLR4)- and TLR3-induced IL-12p35 gene activation
Blood, February 1, 2006; 107(3): 1078 - 1084.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
G. Gautier, M. Humbert, F. Deauvieau, M. Scuiller, J. Hiscott, E. E.M. Bates, G. Trinchieri, C. Caux, and P. Garrone
A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells
J. Exp. Med., May 2, 2005; 201(9): 1435 - 1446.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/53/55609    most recent
M406565200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, J.
Right arrow Articles by Ma, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, J.
Right arrow Articles by Ma, X.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement